A single-institution retrospective cohort of 101 patients receiving ultra-hypofractionated radiation 36.25 Gy to the prostate and 25 Gy to pelvic nodes all in 5 fractions for high-risk prostate cancer favorable rates of both GI (2.9%) and GU (4.9)% late grade 2 events and no late G3 events at a median follow-up of 3.5 years with a promising 5-year biochemical recurrence-free survival of 90%. | Martinez, Pract Radiat Oncol 2026
